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Abstract: 
         Background  and  objectives:  The  functional  polymorphisms  regulating 
immunologic  responses  may  influence  the  proliferation  or  suppression  of  malignant 
lymphoma.  Polymorphism  of  a  specific  gene  can  have  an  important  effect  on  gene 
transcription, the stability of the mRNA, or the quantity and activity of the resulting 
protein.  Interleukin  –1  (IL-1)  gene  cluster  polymorphisms  have  been  shown  to  be 
important  mediators  of  inflammation.  This  study  aimed  to  determine  whether 
polymorphisms  at  IL-1  receptor  antagonist  (IL-1ra)  locus  modulate  the  risk  of 
developing malignant lymphoma. Methods: the hospital-based case-control study was 
conducted in Epidemiology and Genetics Unit, Algernon Firth Building, University of 
Leeds,  LS2  9JT.  Genotypes  were  determined  for  a  variable  length  polymorphism  in 
intron  2  of  the  IL-1ra  gene  (IL-1RN)  using  PCR  based  technique.  Genotypes  were 
examined in a total of 279 lymphoma cases, 60 Hodgkin’s disease (HD) cases and 464 
non-cancer  control  subjects.  Results:  The  overall  allele  distribution  of  these 
polymorphisms did not differ substantially between patients and controls; the odds ratio 
(OR) was 0.72 and 95% confidence interval (CI) was 0.5-1.03 for the allele 2 carriers of 
IL-1RN.  Subgroup  analysis  according  to  histology  [diffuse  large  B-cell  lymphoma 
(DLBC) and follicular cell lymphoma (FCC)] failed to illustrate differences except for 
DLBC which showed a significant deficit of the 2/2 genotype in the older DLBC cases, 
i.e. that  the IL-1RN*2/*2  genotype is  protective for  cases in  the 60-65  years  group 
compared to the 1/1 genotype (OR = 0.25 & 95% CI=0.09 – 0.67). On the other hand 
the IL-1RN*2/*2 genotype was a risk for HD cases (OR=2.27 & 95% CI=1.22-4.24). 
Conclusion: The data of this study show a limited association between IL-1 RN gene 
polymorphisms and malignant lymphoma risk in total. IL-1RN*2/*2 is associated with 
increased risk to HD. The possible protection role/risk association of the IL-1RN*2/*2 
genotype and DLBC/HD respectively needs further clarification. 
     
Introduction 
         Maintaining  the  physiological 
balance  or  homeostasis  is  of  vital 
importance  for  any  living  organism. 
Various  forms  of  endogenous  and 
exogenous  stress  constantly  interfere 
with  this  homeostasis.  As  a  result  of 
genetically determined adaptive poten -
tial, the effect of these stress factors is 
normally compensated, and a new level 
of homeostasis is usually rapidly achie -
ved. The adaptive potential between the 
species  and  between  individuals  of  the 
same species has a great variation. One 
of  the  most  important  population 
genetic  mechanisms  explaining  this 
natural  diversity  is  genetic  polymo  -
rphism  (Steven  et  al,  2002).  Inflam  -
matory stress is the stress form, which is 
constantly  present.  Cytokines  are  a 
group  of  small  soluble  or  cell-
membrane-  bound  protein  or  glycop 
rotein  messenger  molecules  with  high 
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potential in the regulation of inflamm -
atory  responses.  The  balance  of  pro-
inflammatory  and  anti-inflammatory 
cytokines is essential for normal cellular 
function.  Like  most  human  genes,  the 
cytokine  genes  are  also  polymorphic 
(Mwantembe et al, 2001). Some alleles 
of  polymorphic  cytokine  genes  have 
been shown to be associated with vari -
ation  in  cytokine  production  capacity. 
Moreover,  allelic  imbalance  of  several 
cytokine genes has been described in a 
number  of  diseases.  These  complem  -
entary  biological  and  pathological 
associations of cytokine gene polymor -
phism make them an interesting subject 
of  research  (Santtila  et  al  1998). 
Clinically  oriented  genetic  association 
studies  are  of  great  value  as  genetic 
risk-assessment  based  treatment 
strategies  will  become  applicable  in 
clinical  practice  in  the  near  future 
(Sehoulie et al, 2002). 
         Cytokines play important roles  in 
the hematopoietic and immune systems. 
Their  functions  include  control  of 
cellular and humoral immune responses, 
with an impact on inflammation, chem -
otaxis, tumor regression, hematopoiesis, 
and  acute-phase  responses  (Hsu  et  al, 
1993).  Interleukin-1  (IL-1),  which  is  a 
prototypic  multifunctional  cytokine 
synthesized  by  a  variety  of  cell  types, 
including  activated  macrophages  and 
stimulated  B-lymphocytes,  is  an  esse  -
ntial  mediator  of  inflammation  and 
immunity (Cantagrel et al, 1999). It can 
exert  either  inhibitory  or  promoting 
effects on neoplasms including hemat  -
ologic  malignancies  (Nicklin  et  al, 
1994). 
         IL-1  gene  cluster  is  situated  on 
chromosome  2q,  and  is  comprised  of 
three  related  genes  within  a  430-
kilobase  region:  IL-1A,  IL-1B  and  IL-
1RN,  which  encode  the  pro-inflam  -
matory cytokines IL-1 and IL-1 and 
their  endogenous  receptor  antagonist 
IL-1ra,  respectively  (Dinarello,  1996). 
Five  alleles  of  the  IL-1ra  gene  have 
been reported, corresponding to 2, 3, 4, 
5  and  6  copies  of  an  86-bp  variable 
number  of  tandem  repeat  (VNTR) 
located in intron 2. The frequency of the 
individual alleles varies among different 
ethnic  or  geographic  populations,  but 
allele  1  (IL-1RN*1),  is  always  more 
common  than  allele  2  (IL-1RN*2).The 
remaining  alleles,  occurs  in  <1%  of 
most populations. The IL-1RN*2 allele 
enhances  IL-1  production  and  is 
associated  with  several  diseases, 
however  data  regarding  its  effects  on 
IL-1ra  production  are  contradictory 
(Tountas et al, 1999). 
Patients and methods  
  This  study  was  carried  in  the 
Epidemiology  and  Genetics  Unit, 
Algernon  Firth  Building,  University  of 
Leeds, Leeds, LS2 9JT. There were 139 
cases of diffuse large B cell lymphoma 
(DLBC) (aged 25-65 years), 140 cases 
of  follicular  center  cell  lymphoma 
(FCC) (aged 31-65 years) and 60 cases 
of Hodgkin’s disease (HD) (aged 28-45 
years).  All  the  cases  were  identified 
from  multiple  sources  throughout  the 
Yorkshire  region,  in  the  North  of 
England. Archived samples,  comprising 
paraffin  blocks  of  biopsies,  surgical 
specimens, and peripheral blood smears 
were  obtained.  All  cases  were 
histologically validated according to the 
criteria  of  the  Revised  European-
American  classification  of  lymphoid 
Neoplasm  (REAL)  classification 
(Isaacson,  1995),  using  the  standard 
panel  of  markers  utilized  by  the 
hematological  Malignancy  Diagnostic 
Service  (HMDS)  at  Leeds  General 
Infirmary  (LGI)  (CD20,  CD79,  CD10, 
CD5, CD23, CD3, Ki67 and BCL-2). A 
reference  series  of  464  healthy 
population controls  (aged  19-66  years) 
were  collected  as  part  of  an  ongoing 
lymphoma  study  being  carried  out  by Mona Hilmy Alrayes 
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the  Leukemia  Research  Fund  (LRF) 
Epidemiology  and  Genetics  Unit.  Each 
control  provided  a  blood  sample. 
Ethical  approval  to  establish  a  DNA 
repository  for  cases  of  hematological 
malignancy  and  to  carry  out  a  case-
control  comparison  of  genotypes  was 
obtained from Yorkshire MREC. 
IL-1RN  VNTR  (variable  number  of 
tandem repeat) Genotyping. 
  Genomic  DNA  was  extracted 
from  anticoagulated  peripheral  blood 
leukocytes using a standard proteinase k 
digestion and phenol/chloroform extra -
ction  method.  DNA  amplification  was 
done  by  polymerase  chain  reaction 
(PCR)  using  Peltier  thermal  cycle 
(PTC-225).  Each  PCR  reaction  was 
carried  out  with  50  ng  genomic  DNA 
and 1.0 u Ampli Tag Gold polymerase 
(Perkin-Elmer).  For  optimal  amplify  -
cation,  the  mg
2+  concentration  of  the 
reaction buffer was adjusted to 1.5mM. 
Primers: 1L-1RA F 5` GGT CAG AAG 
GGC  AGA  GA3`.  IL-1RA  R  5`  CCC 
CTC AGC AAC ACT CC 3`. Negative 
controls  without  DNA  template  were 
included  with  each  reaction.  PCR 
denaturation 5 min at 94c, (94c 1-min, 
60c  1-min,  72c  1-min)  30  cycles, 
extension  5-min  at  72c.  The  PCR 
products  sizing  were  analyzed  by 
electrophoresis  on  a  2%  agarose  gel 
stained  with  ethidium  bromide 
(Kenemoto  et  al,  2000).  The  products 
were  sized  relative  to  a  100  bp  DNA 
ladder and were coded as follows: allele 
1= 4 repeats (442bp), allele 2= 2 repeats 
(270  bp),  allele  3=  5  repeats  (528bp), 
allele 4= 3 repeats (356 bp), allele 5 = 6 
repeats (614bp); due to the rarity the 3, 
4  and  5  alleles  were  grouped  for 
statistical analysis. 
Statistical Analysis 
  All  odds  ratios  (OR)  and  95% 
confidence  intervals  (CI)  associated 
with  risk  of  lymphoma  were  adjusted 
for sex as well as age as a continuous 
variable,  instead  of  age  –sex  matching 
using  an  unconditional  logistic  regre  -
ssion model. 95%CI value <1 is prote -
ctive and >1 is risky.  Accordance with 
the  Hardy-Weinberg  equilibrium  the 
genotype  frequencies  among  cases  and 
controls  were  also  compared  with  the 
X
2  test.  All  analyses  were  conducted 
using STATA version 7 software.       
Results 
  In total there were 464 controls 
with an age range of 19-66 years, 51.7% 
of  these  were  males.  There  were  139 
cases  of  DLBC,  with  an  age  range  of 
25-65  years,  and  52.2%  of  these  were 
males.  There  were  140  cases  of  FCC, 
with an age range of 31-65 years,  and 
45.6% of these were males. 
Age and sex comparison of controls: 
When the controls were stratified into 3 
age groups, (19-49, 50-59, 60-65 years), 
no  significant  differences  in  genotype 
frequency  in  the  control  population 
were seen, P=0.52. 
          When the controls were stratified 
by  sex,  no  significant  differences  in 
genotype  frequency  in  the  control 
population were seen, P=0.99. 
Age and sex comparison of cases: 
         When all cases were stratified  by 
sex, no significant differences in genot -
ype  frequency  in  the  case  populations 
were  seen,  P=0.66,  for  DLBC  only 
p=0.166, and for FCC only p=0.91. 
         When  the  cases  were  stratified 
into 3 age groups, (19-49, 50-59, 60-65) 
(the  age  groups  basically  being 
determined on  splitting the  data into  3 
reasonably  even  sections),  no  signif  -
icant differences in genotype  frequency 
in the case population (DLBC and FCC) 
were seen, P=0.48. While no significant 
differences  were  seen  for  age  in  either 
the DLBC or FCC groups (p=0.19 and 
p=0.06  respectively),  but  the  IL-
1RN2*/*2  genotype  was  different  for 
older DLBC cases (60-65 years) (table 
1) & (Figure 1).  Interleukin –1 Receptor Antagonist…….. 
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Table 1: Genotype frequencies for IL-1RN genotypes in combined lymphoma cases, DLBC 
and FCC cases, stratified by age. 
DLBC & FCC (n=279)     
Genotype  19-49y %  50-59y%  60-65y%  OR  95%CI 
1/1  26 (49.03)  74 (52.48)  32 (47.06)  1.0  - 
1/2   11 (20.75)  40 (28.37)  18 (26.47)  1.29  0.59 – 2.80 
1/345    1 (1.89)   4 (2.84)    1 (1.47)  1.22  0.13 – 10.95 
2/2  15 (28.3)  23 (16.31)  17 (25.0)  0.65  0.31 – 1.36 
           
DLBC (n=139)     
Genotype  19-49y  50-59y  60-65y     
1/1  10 (34.48)  38 (51.35)  19 (59.38)  1.0  - 
1/2    5 (17.24)  23 (31.08)    5 (15.63)  0.98  0.30 – 3.14 
1/345    1 (3.45)    1 (1.35)    1 (3.13)  0.35  0.03 – 4.24 
2/2  13 (44.83)  12 (16.22)    7 (21.88)  0.25  0.09 – 0.67* 
           
FCC (n=140)     
Genotype  19-49y  50-59y  60-65y     
1/1  16 (66.67)  36 (53.73)  13 (36.11)  1.0  - 
1/2    6 (25)  17 (25.37)  13 (36.11)  1.63  0.57 – 4.63 
1/345    0 (0)    3 (4.48)    0 (0)  0  - 
2/2    2 (8.33)  11 (16.42)  10 (27.78)  3.42  0.72 – 16.25 
           
This table shows that there is a significant  deficit of the IL-1RN*2/*2 genotype in the  older 
DLBC cases in the 60-65 years group compared to the IL-1*1/*1 genotype. 
 
Table 2: IL-1 RN genotypes in combined lymphoma (DLBC and FCC) cases.  
Genotype 
 
Controls (%) 
(n = 464) 
Cases (%) 
(n = 279) 
     OR    95% CI 
1/1  218 (46.98)  132 (50.38)  1.0  - 
1/2  157 (33.84)    69 (26.34)  0.72  0.5 – 1.03 
1/345     8 (1.72)      6 (2.29)  1.23  0.42 – 3.64 
2/2    81 (17.46)    55 (20.99)  1.12  0.74 – 1.68 
There appears to be non-significant protective effect for the IL-RN*1/*2 genotype. 
 
Table 3: IL-1 RN genotypes in DLBC cases (n=139). 
Genotype  Controls (%)  Cases (%)       OR    95% CI 
1/1  218 (46.98)  67 (49.63)  1.0  - 
1/2  157 (33.84)  33 (24.44)  0.68  0.2 – 1.08 
1/345     8 (1.72)   3 (2.22)  1.22  0.31 – 4.72 
2/2   81 (17.46)  32 (23.70)  1.28  0.78 – 2.10 
There appears to be non-significant protective effect for the IL-1RN*1/*2 genotype. 
 
Table 4: IL-1 RN genotypes in FCC cases (n=140). 
Genotype  Controls (%)  Cases (%)  OR  95% CI 
1/1  218 (46.98)  65 (51.18)  1.0  - 
1/2  157 (33.84)  36 (28.35)  0.76  0.48 – 1.21 
1/345  8 (1.72)  3 (2.36)  1.25  0.32 – 4.87 
2/2  81 (17.46)  23 (18.11)  0.95  0.55 – 1.63 
There appears to be non-significant protective effect for the IL-1RN*1/*2 genotype. 
 
Table 5: IL-1 RN genotypes in HD cases (n=60). 
Genotype  Controls (%)  Cases (%)  OR  95% CI 
1/1  218 (46.98)  26 (43.3)  1.0  - 
1/2  157 (33.84)  11 (18.3)  0.58  0.28 – 1.22 
1/345  8 (1.72)  1 (1.7)  1.04  0.12 – 8.71 
2/2  81 (17.46)  22 (36.7)  2.27  1.22 – 4.24* 
This table shows that IL-1RN*2/*2 genotype % is increased in HD cases. 
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Figure 1: Percentage of IL-1RN genotypes among all studied groups. 
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HD                                                                                                                                       
 
 
Figure  4:  PCR/agarose  gel  electrophoresis  of  the  Il-1RN  VNTR  polymorphism 
illustrating the most common genotypes in this study (L=100 base pair ladder molecular 
weight marker & C=control). 
 
Discussion
Interleukin (IL)-1 and IL-1 are major 
proinflammatory  cytokines  that  are 
synthesized  during  infection  and 
inflammatory  processes.  IL-1RA 
competes for the same IL-1 receptor as 
that  for  IL-1  and  IL-1,  thus 
Figure  2:  Percentage  of  Il-1RN 
genotypes  among  controls  and  HD 
groups. 
Figure 3: Percentage of IL-1RN  genotypes 
stratified by age  among  DLBC cases.                                                                                                                                                                   
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modulating  the  potentially  injurious 
effects of IL-1 (Arend et al, 1998). The 
gene for  IL-1ra  is  located  on  the  long 
arm of the chromosome 2 on a 430 kb 
stretch of DNA. Intron 2 of the IL-1ra 
gene  contains  a  variable  number  of 
identical tandem repeats (VNTR) of an 
86 base pair length of DNA (Nicklin et 
al,  1994).  IL-1RN*2  has  been  assoc  -
iated with decreased IL-1ra levels, and 
consequently  increased  IL-1  levels 
(Andus et al, 1997). The central role of 
the  IL-1  system  is  protection  against 
many  different  insults,  ranging  from 
microbial  colonization  to  infection  to 
malignant  transformation.  The  relative 
levels  of  IL-1-RA  and  IL-1  at  an 
inflammatory  site  will  thus  determine 
whether  a  proinflammatory  response 
will  be  initiated  and  persist  or  will  be 
terminated. Biological functions of IL-1 
on  hematologic  malignancies  have 
therefore already pointed out (Dinarello, 
1996). IL-1B has anti-neoplastic activ -
ity  through  activation  of  the  immune 
system. The higher incidence of hemat -
ologic  malignancies  among  immune 
deficiency  individuals  suggests  that  the 
differences  in  the  status  of  immune 
activation  may  change  the  predispo  -
sition  to  hematologic  malignancy 
(Santavenere et al 1994). 
         The data of this study did not find 
any  difference  in  genotype  frequencies 
of  IL-1RN  between  malignant  lymph  -
oma  patients  as  a  whole  and  control 
subjects.  On  the  other  hand  this  study 
confirmed a mild over expression of IL-
1RN2  */2*  in  malignant  lymphoma 
cases  (DLBC  &  FCC),  which  was  not 
statistically  significant  (controls 
17.46%,  DLBC  23.7%  and  FCC 
18.11%).  The  allelic  frequency  of  IL-
1RN2*/2* was lower in this study than 
found  in  the  study  of  Rollinson  et  al 
(2003) (controls 8% and gastric lymp -
homa  33.9%).  Excess  in  risk  of  the 
malignant  lymphoma  have  been  desc  -
ribed  for  patients  with  various  condi  -
tions  involving  substantial  immune 
dysfunction,  particularly  conditions 
where  chronic  antigenic  stimulation  is 
present  (Machado  et  al,  2001).  The 
consideration  of  polymorphisms  invo  -
lved in the immune response, in combi -
nation  with  those  involved  with  the 
prevention of DNA damage, and further 
those  involved  in  DNA  repair,  could 
allow  the  mechanisms  underlying  these 
associations to be explored further. 
         Subgroup  analyses  according  to 
histologic  subtypes  showed  a  possible 
difference in DLBC. When DLBC cases 
were stratified into 3 age groups, the IL-
1RN2*/2*  genotype  in  the  older  cases 
(60-65 year group) showed a protective 
effect  when  compared  to  IL-1  1*/1* 
genotype (OR=0.25 and 95% CI=0.09 – 
0.67). Steven et al (2002) reported that 
it  might  be  expected  that  people  who 
were  IL-1RN*2  homozygous  (IL-1RN 
*2/*2) might have a genetic  advantage 
in  cancer  prevention  because  this 
genotype is associated with low level of 
IL-1ra  and  elevated  level  of  IL-1 
(which has anti-neoplastic activity) with 
prolonged  and  more  severe  inflam  -
matory  reactions.  These  results  with 
malignant  lymphoma  was  consistent 
with  the  study  done  by  Matsuo  et  al 
(2001), who suggested that, the effects 
of  IL-1  family  gene  polymorphisms  in 
lymphoid  maligna  -ncies  seem  to  be 
limited. On the other hand Rollinson et 
al (2003) reported a significant assoc -
iation  between  gastric  marginal  zone 
lymphoma and inhe -ritance of IL-1RN 
2*/2*  genotype.  Also  El-Omar  et  al 
(2000) reported that IL-1RN*2 homoz -
ygous carriers were at increased risk for 
developing  gastric  carcinoma.  They 
explained  their  results  by  confirming 
that both IL-1B and IL-1RN polymor -
phisms  enhance  IL-1B  expression, 
which are associated with an  increased 
risk of gastric carcinoma. Sehoulie et al Mona Hilmy Alrayes 
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(2002) reported elevated level of IL-1 
at the homozygous for IL-1RN*2 which 
was  associated  with  gastric  cancer. 
Demeter  et  al  (1996)  found  in  a  small 
group study of patients with secondary 
AML  that  the  frequency  of  IL-1RN*4 
allele  appeared  to  be  significantly 
increased.   
         The  data  of  this  study  revealed 
that the IL-1RN2*/2* genotype was in 
36.7%  of  HD  cases  compared  to 
17.46%  in  the  control  reference 
population, showing an association with 
increased risk of HD (OR=2.27 & 95% 
CI= 1.22-4.24). It is postulated that the 
association  between  IL-1RN*2  allele 
with HD was due to impaired produc -
tion of IL-1ra and the high IL-1 levels 
associated  with  Il-1RN*2  allele 
(Tountas  et  al,  1999).  IL-1  favour  a 
proinflammatory response with substa -
ntial  immune  dysfunction,  which  may 
therefore increases risk of DNA damage 
and lymphomagenesis.  Although poly  -
morphism in IL-1RA gene was assoc -
iated  with  various  malignant  diseases, 
data is lacking for HD. 
         In  conclusion,  the  present  study 
revealed  that  genotype  frequencies  of 
IL-1RN gene polymorphism do not vary 
between  malignant  lymphoma  patients 
and non-cancer controls. This is proba -
bly due to the genetic background of the 
patients studied. IL-1RN*2/*2 is assoc -
iated  with  increased  risk  to  HD.  The 
biological  mechanism  of  this  difference 
is  unclear.  The  apparent  relationship 
between IL-1RN*2/*2 and both lymp -
homa and HD raises the possibility that 
another  nearby  gene  polymorphism 
might be responsible for some of these 
associations.  The  results  of  this  study 
provide  useful  information  to  explore 
the susceptibility to lymphoma and HD, 
which  it  would  be  valuable  to  inves  -
tigate  further  in  larger  studies  among 
Egyptians. 
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ضه ثروه لكش ددعت نيكولرتنإ لبقتسه دا - 1    تيوافويللا مارولأا و
تيناطارسلا  
سيرلا ىولح ىنه  
  ثانبلا بط تيلكب تيئايويكلا و تيكينيلكلأا ايجولوحابلا نسق - رهزلأا تعهاج  
 
 ًازووا دااَخإ وأ سشانذ يف وخدري دق حيػاَْىا حتاجرس لإى ٌظَْىا يفيظوىا ونشىا ددؼذ ُأ دجو دقى
حيوافَييىا حيّاطسسىا . َم  وأ ززواَىا ماسّ يايػ ًااا سيشثاذ هى ُوني دق ِيؼٍ ززوٍ ونش ددؼذ ُأ ا
أ ُ ز هاسسَىا ىووْىا ضٍاحىا زاسقرسإ  ,  ذااْىا ِيذوساثىا طااشّ و حايَم ياف وأ  .  دداؼذ سارظأ داقف
ِيموىسرّإ ززوٍ حطاثس ونش - 1   خاتاررىلإا يف ظيسوم حريَاأ .  
جحبلا فده :  
 هانشأ ددؼذ ُام اذإ اٍ ديدحذ وا سحثىا فدا ِيمواىسرّإ وثقراسٍ دااضٍ غقوٍ - 1     ااَّإ ه  داؼي
؟ارٍْ يَحي وأ حيوافَييىا حيّاطسسىا ًازووا  
تقرط و جحبلا ةداه :  
            اسريجّاات شدايى حاؼٍاج ياف خاايياتوىا و خااشزوَىا جدحو يف حسازدىا ديسجأ دقى  .  دايدحذ ٌاذ داقو
 وثقراسٍ دااضٍ  ززواٍ حطاثاس ونش ددؼذ و هوط فلارخلا ززوَىا عوّ ِيمواىسرّإ - 1    ُوساْذإ ياف 2   
جسااَيثىا حيااسيس وااػافذ حاايْقذ ًادارااسات  . يىاااَجإ يااف ززوااَىا عوااّ زاااثرخإ ٌااذ اااَم 272    ًازومااى حااىاح
ِيريػسف ِيرػوَجٍ ييػ ديَرشإ يرىا و حيّاطسسىا حيوافَييىا  : 132    جساشرَْىا حايوافَييىا ًازومى حىاح
ايلاايى -  و جسيثنىا ب 141   يى حيوافَييىا ًازومى حىاح  ياىإ حفااة لإاات لاىذ و حياصوحرَىا ايلاا 01    حاىاح
 لىرم و صْينجدوا ضسَى 404   حطتاة حػوَجَم  احصوا ٍِ صاش .  
جحبلا جئاتن :  
           دداؼرى حثاسْىات ًشلااَىا غايشوذ ياف اايساوج اافلارخا ًواَؼىا حاجو ييػ دجوي لا حّأ سحثىا سرظأ
ِيمواىسرّإ وثقراسٍ دااضٍ ززواٍ حطاثاس هانشأ - 1   ياةسَىا ِيات   حطتااضىا حاػوَجَىا و  .  واشف لىرام
 ًازووا حااػوَجٍ ادااػ اااَيف خااافلارخا داااضيإ يااف يجيااسْىا عوااْريى اااقثط حاايػسفىا غيٍاااجَيى وااييحرىا
ايلاايى جسشرَْىا حيوافَييىا -  ززواَىا عواّ ياف ٌارٍ صاجػ خسارظأ يارىا جسايثنىا ب 2 \ 2    حاػوَجَىا ياف
حيػسفىا حػوَجَىا جرا يف اْس سثموا حيسَؼىا  .  و اَْيت  ياف حاَرٍ جدايش كاْا ُام سخلآىا ةّاجىا ييػ
 ززوَىا عوّ 2 \ 2   صْينجدوا ضسٍ خلااح يف .  
                                                                         ثايصوتلا و جاتنتسلإا  
 وثقراااسٍ دااااضٍ ززواااٍ وناااش دداااؼذ ِيااات جدوداااحٍ حثحاااا ٍ حاااسازدىا جراااا خااااّايت خسااارظأ
ِيموىسرّإ - 1    و ونم حيّاطسسىا حيوافَييىا ًازووأ سطخ  .  عواّ حثحاا ٍ ساطخ حاسازدىا خسارظأ لىرام
 ززوَىا 2 \ 2   ِيموىسرّإ وثقرسٍ داضَى - 1    صْينجدوا ضسٍ غٍ  .  حثحاا ٍ ساطخ حاسازدت يصوي و \  
 ززواَىا عوّ  حياَح وأ 2 \ 2   ِيمواىسرّإ وثقراسٍ دااضَى - 1   اايلاايى جساشرَْىا حايوافَييىا ًازووا غاٍ -  ب
 جسيثنىا \    و ِييس َىا يةسَىا يف  صْينجدوا ضسٍ .  
 